Showing results (51-60 of 243) with videos related to

Sort By:
Pageof 25
Journal of Cellular Biochemistry|April 7, 2009
Regucalcin is under-expressed in human breast and prostate cancers: Effect of sex steroid hormonesCláudio Maia, Cecília Santos, Fernando Schmitt, et al.
Genes|March 28, 2026
MicroRNA-Gene Networks Distinguish Hormone Receptor Status in HER2-Low Breast Cancer: An Integrative Transcriptomic AnalysisEduarda Carvalho, Andreia Brandão, Fernando Schmitt, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 10, 2008
Evaluation of parathyroid gland angiogenesis in chronic kidney disease associated with secondary hyperparathyroidismPatrícia Martins, Fernando Schmitt, Henrique Almeida, et al.
Virchows Archiv : an International Journal of Pathology|June 7, 2014
Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotypeMiguel Rito, Fernando Schmitt, António E Pinto, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|September 3, 2023
Next-Generation Sequencing of Breast Cancer in the Neoadjuvant SettingAlexandra Mesquita, Anabela Ferro, José Carlos Machado, et al.
BMC Biotechnology|September 11, 2009
A comparative study of recombinant and native frutalin binding to human prostate tissuesCarla Oliveira, José A Teixeira, Fernando Schmitt, et al.
Cancer Cytopathology|April 15, 2025
Cytology-Radiology Correlation Series: Pancreatic cytopathologyJudy Trieu, Andrew Gilman, Katerina Konstantinoff, et al.
Diagnostic Cytopathology|February 27, 2013
Thyroid fine-needle aspiration cytology: is there a place to virtual cytology?Renê Gerhard, Sofia Teixeira, Adriana Gaspar da Rocha, et al.
Angiogenesis|August 11, 2004
Glutathione S-transferase genotype GSTM1 as a predictor of elevated angiogenic phenotype in patients with early onset breast cancerRui Medeiros, Raquel Soares, André Vasconcelos, et al.
Molecular Biology Reports|November 5, 2021
Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkersFlávia Miranda, Hugo Prazeres, Fernando Mendes, et al.
Pageof 25